Leukaemia-associated mutations almost inevitable as we age

Researchers estimate that 7 in 10 over 90-year-olds harbour cells with early leukaemia mutations

Leukaemia-associated mutations almost inevitable as we age

150226-leukaemia.pngDOI: 10.1016/j.celrep.2015.02.005
Some gene mutations only drive expansion of pre-leukaemic cells in advanced old age and in the context of an ageing haemopoietic system.

It is almost inevitable that we will develop genetic mutations associated with leukaemia as we age, according to research published today in Cell Reports. Based on a study of 4219 people without any evidence of blood cancer, scientists estimate that up to 20 per cent of people aged 50-60 and more than 70 per cent of people over 90 have blood cells with the same gene changes as found in leukaemia.

Scientists investigating the earliest stages of cancer development used an exquisitely sensitive sequencing method capable of detecting DNA mutations present in as few as 1.6 per cent of blood cells, to analyse 15 locations in the genome, which are known to be altered in leukaemia. By comparing their findings with other research conducted with a lower degree of sensitivity over whole exomes, the scientists were able to conclude that the incidence of pre-leukaemic cells in the general population is much higher than previously thought and increases dramatically with age.

"Leukaemia results from the gradual accumulation of DNA mutations in blood stem cells, in a process that can take decades. Over time, the probability of these cells acquiring mutations rises. What surprised us was that we found these mutations in such a large proportion of elderly people. This study helps us understand how aging can lead to leukaemia, even though the great majority of people will not live long enough to accumulate all the mutations required to develop the disease."

Dr Thomas McKerrell, joint first author from the Wellcome Trust Sanger Institute

None of the 4219 people studied were found to have a mutation in NPM1, the most common acute leukaemia gene mutated in up to 40 per cent of cases. This unexpected result suggests that mutations in NPM1 behave as gatekeepers for this cancer; once a mutation in this gene occurs in a cell with particular previously accumulated pre-leukaemic mutations, the disease progresses rapidly to become leukaemia.

"The significance of mutations in this gene is astonishingly clear from these results: it simply doesn't exist where there is no leukaemia. When it is mutated in the appropriate cell, the floodgates open and leukemia is then very likely to develop. This fits with studies we've conducted in the past in which we found that the gene primes blood stem cells for leukaemic transformation."

Dr Naomi Park, joint first author from the Sanger Institute

Leukaemia serves as a useful model for research into the origins of cancer because blood samples are much easier to obtain than tissue samples. Each cancer begins with a single mutation in just one cell; this research allows scientists to look at how these first mutated cells accumulate to form cancer.

"Ultra-deep sequencing has allowed us to see the very beginnings of cancer. These mutations will be harmless for the majority of people but for a few unlucky carriers they will take the body on a journey towards leukaemia. We are now beginning to understand the major landmarks on that journey."

Dr George Vassiliou, senior author from the Sanger Institute and Cambridge University Hospitals NHS Trust

Notes to Editors
Publications
  • Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis.

    McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H et al.

    Cell reports 2015;10;8;1239-45

Funding

This project was funded by a Wellcome Trust Clinician Scientist Fellowship (TM) and by the Wellcome Trust Sanger Institute (grant number WT098051). GV is funded by a Wellcome Trust Senior Fellowship in Clinical Science (Wt095663MA) and work in his laboratory is also funded by Leukaemia & Lymphoma Research and the Kay Kendall Leukaemia Fund. IV is funded by Spanish Ministerio de Economía y Competitividad subprogram Ramón y Cajal.

Participating Centres
  • Wellcome Trust Sanger Institute
  • Universidad de Cantabria
  • University of Cambridge
  • NHS Blood and Transplant
  • Institute for Social and Economic Research at the University of Essex
  • Cambridge University Hospitals NHS Trust
  • Technische Universität München
  • German Cancer Research Center
Selected website
Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

From childhood cancer to mapping human development: Pioneering scientist awarded 2019 Foulkes Foundation medal
Congratulations to Professor Muzlifah Haniffa, who has been recognised for her work on the immune system and childhood cancer
Dr Sam Behjati wins Liddy Shriver Early Career Research Award
Congratulations to Sanger Institute cancer researcher, Dr Sam Behjati, who has been recognised for his work in sarcoma cancer genomics
New malaria drug targets identified in liver stage of life cycle
Hope that new liver-stage drugs will help to counter the threat of antimicrobial resistance to current blood-stage medicines